The Relationship between the Plasma PCSK9 Levels and Platelet Indices in Patients With Stable Coronary Artery Disease

Journal of Atherosclerosis and Thrombosis

Volumn 22, Issue 1, 2015, Pages 76-84

  Li, Sha ^a   Zhu, Cheng Gang ^a   Guo, Yuan Lin ^a   Xu, Rui Xia ^a   Zhang, Yan ^a   Sun, Jing ^a   Li, Jian Jun ^a  

^a FUWAI HOSPITAL   (China)

Author keywords

Coronary artery disease; Platelet count; Proprotein convertase subtilisin kexin type 9

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; FIBRINOGEN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; SERINE PROTEINASE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; PCSK9 PROTEIN, HUMAN;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOMETABOLIC RISK; COMPUTER ASSISTED TOMOGRAPHY; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; LABORATORY TEST; LEUKOCYTE COUNT; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; RISK FACTOR; THROMBOCYTE COUNT; THROMBOCYTE VOLUME; BLOOD; FOLLOW UP; MIDDLE AGED; PATHOLOGY; PROGNOSIS; THROMBOCYTE;

BIOMARKERS; BLOOD PLATELETS; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PLATELET COUNT; PROGNOSIS; PROPROTEIN CONVERTASES; SERINE ENDOPEPTIDASES;

EID: 84921881475     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.25841     Document Type: Article

References (23)

1. Park BJ, Shim JY, Lee HR, Jung DH, Lee JH, Lee YJ: The relationship of platelet count, mean platelet volume with metabolic syndrome according to the criteria of the American Association of Clinical Endocrinologists: A focus on gender differences. Platelets, 2012; 23: 45-50
2. Santimone I, Di Castelnuovo A, De Curtis A, Spinelli M, Cugino D, Gianfagna F, Zito F, Donati MB, Cerletti C, de Gaetano G, Iacoviello L: White blood cell count, sex and age are major determinants of heterogeneity of platelet indices inan adult generalpopulation: results fromthe MOLI-SANI project. Haematologica, 2011; 96: 1180-1188
3. Thaulow E, Erikssen J, Sandvik L, Stormorken H, Cohn PF: Blood platelet count and function are related to total and cardiovascular death in apparently healthy men. Circulation, 1991; 84: 613-617
4. Van der Bom JG, Heckbert SR, Lumley T, Holmes CE, Cushman M, Folsom AR, Rosendaal FR, Psaty BM: Platelet count and the risk for thrombosis and death in the elderly. J Thromb Hemost, 2009; 7: 399-405
5. O'Donnell VB, Murphy RC, Watson SP: Platelet lipidomics: modern day perspective on lipid discovery and characterization in platelets. Circ Res, 2014; 114: 1185-1203
6. Urban D, Pöss J, Böhm M, Laufs U: Targeting the proprotein convertase subtilisin/kexin Type 9 for the treatment of dyslipidemia and atherosclerosis. J Am Coll Cardiol, 2013; 62: 1401-1408
7. Li S, Guo YL, Xu RX, Zhang Y, Zhu CG, Sun J, Qing P, Wu NQ, Jiang LX, Li JJ: Association of plasma PCSK9 levels with white blood cell count and its subsets in patients with stable coronary artery disease. Atherosclerosis, 2014; 234: 441-445
8. Sun X, Essalmani R, Day R, Khatib AM, SeidahNG, Prat A: Proprotein convertase subtilisin/kexin type 9 deficiency reduces melanoma metastasis in liver. Neoplasia, 2012; 14: 1122-1131
9. Cui Q, Ju X, Yang T, Zhang M, Tang W, Chen Q, Hu Y, Haas JV, Troutt JS, Pickard RT, Darling R, Konrad RJ, Zhou H, Cao G: Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population. Atherosclerosis, 2010; 213: 632-636
10. Werner C, Hoffmann MM, Winkler K, Böhm M, Laufs U.: Risk prediction with proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with stable coronary disease on statin treatment. Vascul Pharmacol, 2014; S1537-1891(14) 00057-3
11. Denis M, Marcinkiewicz J, Zaid A, Gauthier D, Poirier S, Lazure C, Seidah NG, Prat A: Gene inactivation of proprotein convertase subtilisin/kexin type 9 reduces atherosclerosis in mice. Circulation, 2012; 125: 894-901
12. Stock J: Improving the care of high-risk patients: the potential of PCSK9. Atherosclerosis, 2014; 232: 420-422
13. Guo YL, Liu J, Xu RX, Zhu CG, Wu NQ, Jiang LX, Li JJ: Short-term impact of low-dose atorvastatin on serum proprotein convertase subtilisin/kexin type 9. Clin Drug Invest, 2013; 33: 877-883
14. Le Bras M, Roquilly A, Deckert V, Langhi C, Feuillet F, Sébille V, Mahé PJ, Bach K, Masson D, Lagrost L, Costet P, Asehnoune K, Cariou B: Plasma PCSK9 is a late biomarker of severity in patients with severe trauma injury. J Clin Endocrinol Metab, 2013; 98: E732-E736
15. Endler G, Klimesch A, Sunder-Plassmann H, Schillinger M, Exner M, Mannhalter C, Jordanova N, Christ G, Thalhammer R, Huber K, Sunder-Plassmann R: Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease. Br J Haematol, 2002; 117: 399-404
16. De Luca G, Santagostino M, Secco GG, Cassetti E, Giuliani L, Franchi E, Coppo L, Iorio S, Venegoni L, Rondano E, Dell'Era G, Rizzo C, Pergolini P, Monaco F, Bellomo G, Marino P: Mean platelet volume and the extent of coronary artery disease: results from a large prospective study. Atherosclerosis, 2009; 206: 292-297
17. Vizioli L, Muscari S, Muscari A: The relationship of mean platelet volume with the risk and prognosis of cardiovascular diseases. Int J Clin Pract, 2009; 63: 1509-1515
18. Pathansali R, Smith N, Bath P: Altered megakaryocyteplatelet haemostatic axis in hypercholesterolaemia. Platelets, 2001; 12: 292-297
19. Martin JF, Slater DN, Kishk YT, Trowbridge EA: Platelet and megakaryocyte changes in cholesterol induced experimental atherosclerosis. Arteriosclerosis, 1985; 5: 604-612
20. Feingold KR, Moser AH, Shigenaga JK, Patzek SM, Grunfeld C: Inflammation stimulates the expression of PCSK9. Biochem Biophys Res Commun, 2008; 374: 341-344
21. Tang Z, Jiang L, Peng J, Ren Z, Wei D, Wu C, Pan L, Jiang Z, Liu L: PCSK9 siRNA suppresses the inflammatory response induced by oxLDL through inhibition of NF-kB activation in THP-1-derived macrophages. Int J Mol Med, 2012; 30: 931-938
22. Ceresa IF, Noris P, Ambaglio C, Pecci A, Balduini CL: Thrombopoietin is not uniquely responsible for thrombocytosis in inflammatory disorders. Platelets, 2007; 18: 579-582
23. Blann AD, Kuzniatsova N, Lip GY: Vascular and platelet responses to aspirin in patients with coronary artery disease. Eur J Clin Invest, 2013; 43: 91-99